NEXI-001
Phase 1b Expansion Study of Multi-Antigen Specific CD8+ T Cells After Decitabine-enhanced Lymphodepletion: an Adoptive Cellular Therapy for Patients with Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation from Matched HLA Donors
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 31 patients (estimated)
- Sponsors
- City of Hope Medical Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Allogeneic Stem Cell Transplant, T Cell (Allogeneic), Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 2007
- NCT Identifier
- NCT06572631
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.